Co-Diagnostics Shares Rise 21% After Submitting FDA Application For Covid-19 Test Platform
28 December 2023 - 5:07AM
Dow Jones News
By Ben Glickman
Shares of Co-Diagnostics rose on Wednesday after the company
submitted an application to the Food and Drug Administration for
its Covid-19 test platform.
The stock was up 21% to $1.39 in midday trading. Shares are down
46% this year.
The Salt Lake City-based company said it had submitted its Co-Dx
PCR Covid-19 test to the FDA for Emergency Use Authorization. The
company's submission includes its PCR Pro instrument, the Covid-19
detection test and an associated mobile app.
Co-Diagnostics said its polymerase chain reaction technology has
been shown in evaluations to detect Covid-19 in nasal swabs with
results shown on the app within 30 minutes.
The company is also developing its Co-Dx platform to test for
tuberculosis, HPV and certain other respiratory viruses.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
December 27, 2023 12:52 ET (17:52 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.